- Global Pharma News & Resources


DGAP-News: Defence Therapeutics Inc. / Key word(s): Patent
31.08.2021 / 08:30
The issuer is solely responsible for the content of this announcement.



Vancouver, BC, Canada, August 31st, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on ADC therapeutics for cancer targeting with its AccumTM technology and cancer vaccine therapeutics and infectious disease vaccines is pleased to announce the expansion of its patent portfolio through the filing of its AccumTM technology-based USA Provisional Patent Application named "Steroid Acid-Based Hydrogels".

Hydrogels are cross-linked polymer networks that can swell and retain a significant amount of water within its structure. Hydrogels are commonly used in various industries and have a wide variety of applications such as pharmaceuticals and therapeutics (drug delivery systems), biomedical, food additives, cosmetics (hygienic products), environmental, energy, agriculture as well as the mining industry for dewatering.

Defence's novel AccumTM hydrogel was spontaneously formed within a matter of seconds immediately following resuspension at room temperature. Hydrogel formation was evaluated upon dissolution of the different AccumTM variants peptide or steroid acid-peptide AccumTM variants in different aqueous solvents. The kinetics of hydrogel formation was found to be dependent on the steroid acid-peptide conjugate, concentration of the steroid acid-peptide conjugate, as well as the aqueous solvent used.

"The hydrogels sector is growing at a fast pace and Defence's versatility of its AccumTM technology gives Defence another business opportunity that the Defence team is planning to advance to a commercialization level. Defence will be a participant in this emerging market, with our lab-based studies that have clearly demonstrated the positive result in that different steroid acid-hnRNPA1 (an AccumTM variants) spontaneously and rapidly forms a new hydrogel when dissolved in various aqueous solvents at different temperatures and concentrations. By its versatility, Defence's novel AccumTM hydrogel will be able to target the personal specific needs of each customer" said S├ębastien Plouffe, Chief Executive Officer of Defence.

According to the new report by Expert Market Research titled "Global Hydrogel Market Size, Share, Price, Trends, Growth, Analysis, Report and Forecast 2021-2026", the global hydrogel market is an effervescence field with a revenue of $23.6 billion in 2020 and an expected CAGR of 7.0% over the next five years to reach $35.5 billion in 2026. The diverse used application of hydrogel such as Medical Fields, Industrial Fields, Consumer Goods will drive the Hydrogel market.

Key players in the biotech/pharma industry are Alcon (Novartis AG), Johnson & Johnson Services Inc. and 3M Company.

About Defence:
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

31.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Defence Therapeutics Inc.
1680 - 200 Burrard St
V6C3L6 Vancouver
ISIN: CA24463V1013
Listed: Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto
EQS News ID: 1229908

End of News DGAP News Service

Editor Details

Last Updated: 31-Aug-2021